Notas de prensa

  • 20 de octubre de 2006
  • 123

U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit

Court Will Proceed on the Merits of Amgen´s Claim That Roche´s peg-EPO Infringes Amgen´s EPO Patents

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 20, 2006--Amgen (NASDAQ:AMGN) announced that a U.S. Federal District Court in Boston today denied Roche´s motion to dismiss Amgen´s patent infringement lawsuit against Roche. The court today also denied a motion by Ortho Biotech to intervene as a co-plaintiff in the case.

"The judicial process can now move forward towards resolution of the substantive issue of patent infringement and we look forward to addressing the merits of this case," said David Scott, Amgen´s senior vice president, general counsel and secretary.

Amgen continues to believe that Roche´s peg-EPO product violates Amgen´s patents and does not provide any clinical or patient benefit over Amgen´s innovative therapies, EPOGEN(R) (Epoetin alfa) and Aranesp(R) (darbepoetin alfa).

Amgen revolutionized anemia treatment with the introduction of EPOGEN. EPOGEN, along with Aranesp, represent over four million combined patient-years of experience. Amgen has continued to invest heavily in research to improve the lives of patients with kidney, cancer and cardiovascular disease.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science´s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people´s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

EDITOR´S NOTE: An electronic version of this news release may be accessed via our Web site at www.amgen.com. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Media section of the Web site.

CONTACT: Amgen, Thousand Oaks Marie Fay, 805-447-0081 (media) Arvind Sood, 805-447-1060 (investors) SOURCE: Amgen

Destacadas

  • IMMUNOCORE anuncia la inclusión de KIMMTRAK (tebentafusp) en la prestación farmacéutica del Sistema Nacional de Salud

    Verónica SF

    IMMUNOCORE anuncia la inclusión de KIMMTRAK (tebentafusp) en la prestación farmacéutica del Sistema Nacional de Salud

    Leer más
  • La Cátedra Galapagos de la Universidad de Cantabria otorga los  II Premios sobre Economía de la Salud

    Vanesa Vicente

    La Cátedra Galapagos de la Universidad de Cantabria otorga los II Premios sobre Economía de la Salud

    Leer más
  • Kyowa Kirin se suma a la campaña de FEDER con motivo del Día Mundial de las Enfermedades Raras

    Alba Martín

    Kyowa Kirin se suma a la campaña de FEDER con motivo del Día Mundial de las Enfermedades Raras

    Leer más

Newsletter

Suscríbete para conocer las novedades del mundo farmacéutico y sanitario.

¿Qué es?

FarmaNews pone a disposición de los medios y departamentos de comunicación, un canal para publicar notas de prensa y convocatorias del mundo sanitario y farmacéutico.

Contacto

C/ Pau Clarís, 21, local 2
08780, Pallejà, Barcelona